JP2007510714A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510714A5
JP2007510714A5 JP2006538993A JP2006538993A JP2007510714A5 JP 2007510714 A5 JP2007510714 A5 JP 2007510714A5 JP 2006538993 A JP2006538993 A JP 2006538993A JP 2006538993 A JP2006538993 A JP 2006538993A JP 2007510714 A5 JP2007510714 A5 JP 2007510714A5
Authority
JP
Japan
Prior art keywords
formulation
statin
hours
transporting
rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510714A (ja
Filing date
Publication date
Priority claimed from US10/967,167 external-priority patent/US8987322B2/en
Application filed filed Critical
Publication of JP2007510714A publication Critical patent/JP2007510714A/ja
Publication of JP2007510714A5 publication Critical patent/JP2007510714A5/ja
Pending legal-status Critical Current

Links

JP2006538993A 2003-11-04 2004-10-29 担体輸送スタチンの医薬製剤およびそれらの使用 Pending JP2007510714A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51677003P 2003-11-04 2003-11-04
US10/967,167 US8987322B2 (en) 2003-11-04 2004-10-19 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
PCT/IB2004/003849 WO2005041939A1 (en) 2003-11-04 2004-10-29 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof

Publications (2)

Publication Number Publication Date
JP2007510714A JP2007510714A (ja) 2007-04-26
JP2007510714A5 true JP2007510714A5 (cg-RX-API-DMAC7.html) 2007-11-29

Family

ID=34556205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538993A Pending JP2007510714A (ja) 2003-11-04 2004-10-29 担体輸送スタチンの医薬製剤およびそれらの使用

Country Status (9)

Country Link
US (2) US8987322B2 (cg-RX-API-DMAC7.html)
EP (2) EP1682095B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007510714A (cg-RX-API-DMAC7.html)
AU (1) AU2004284884A1 (cg-RX-API-DMAC7.html)
CA (1) CA2543716C (cg-RX-API-DMAC7.html)
ES (2) ES2509869T3 (cg-RX-API-DMAC7.html)
IL (1) IL175134A0 (cg-RX-API-DMAC7.html)
NO (1) NO20062432L (cg-RX-API-DMAC7.html)
WO (1) WO2005041939A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
WO2007071357A2 (en) * 2005-12-20 2007-06-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
WO2007103453A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
WO2008154339A2 (en) * 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
TR200800269A2 (tr) * 2008-01-15 2009-08-21 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Stabil farmasötik formülasyon ve hazırlama yöntemleri
TWI391150B (zh) * 2008-01-22 2013-04-01 Taiwan Biotech Co Ltd 腸溶性長效塗覆芯與藥物劑型及其製造方法
WO2009095934A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
US20090280169A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4088884A (en) * 1976-01-26 1978-05-09 The United States Of America As Represented By The Secretary Of The Navy Wide aperture optical communications detector
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4557925A (en) 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
CA2045428A1 (en) 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2002538202A (ja) * 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド HMG−CoAレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
AU5340101A (en) * 2000-04-11 2001-10-23 Atherogenics Inc Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US20020147232A1 (en) * 2000-05-26 2002-10-10 Claus Sundgreen Pharmaceutical compositions comprising desglymidodrine as an active drug substance
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
MXPA04006780A (es) 2002-01-11 2005-06-08 Athpharma Ltd Formulaciones farmaceuticas de pravastatina y metodos para usarlas.
US20040132802A1 (en) 2002-09-03 2004-07-08 Jackie Butler Pharmaceutical formulations and methods for modified release of statin drugs
US20040132806A1 (en) 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use

Similar Documents

Publication Publication Date Title
RU2470016C2 (ru) Производное бипиразола
JP2010522208A5 (cg-RX-API-DMAC7.html)
FI3810201T3 (fi) GIP/GLP1-agonistin koostumuksia
MXPA05010422A (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad.
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
JP2009235100A5 (cg-RX-API-DMAC7.html)
JP2005289996A5 (cg-RX-API-DMAC7.html)
JP2007511487A5 (cg-RX-API-DMAC7.html)
JP2005263780A5 (cg-RX-API-DMAC7.html)
CY2013023I1 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεος ως το ενεργο συστατικο
HRP20140391T1 (hr) Spojevi i pripravci tioacetata, te postupci uporabe
JP2008531742A5 (cg-RX-API-DMAC7.html)
JP2006271392A5 (cg-RX-API-DMAC7.html)
HK1049158A1 (zh) 药物活性异二氢吲衍生物
NO20044487L (no) Kombinasjon av organiske forbindelser
TW200502008A (en) Patches for mucosa of oral cavity containing fentanyl
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
RU2010136914A (ru) Средство и продукт питания для профилактики/уменьшения проявлений функционального расстройства пищеварения
JP2006517944A5 (cg-RX-API-DMAC7.html)
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
JP2005519052A5 (cg-RX-API-DMAC7.html)
JP2011516544A5 (cg-RX-API-DMAC7.html)
WO2008020314A3 (en) Statin stabilizing dosage formulations
CA2565993A1 (en) Salt of 4-or 5- aminosalicylic acid